Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT04433858
PHASE2
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
Sponsor: Sheppard Pratt Health System
View on ClinicalTrials.gov
Summary
The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg) administered under supportive conditions to adult participants with severe TRD, in improving depressive symptoms.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
27
Start Date
2021-03-01
Completion Date
2026-05-01
Last Updated
2024-08-09
Healthy Volunteers
No
Conditions
Interventions
DRUG
Psilocybin
open-label
Locations (2)
VA Palo Alto Healthcare System/Stanford Medicine
Palo Alto, California, United States
Sheppard Pratt Health System
Baltimore, Maryland, United States